| Literature DB >> 34781639 |
Naeun Kwak1, Min Ji Park1, Hea Min Jang1, Hee Sun Baek1, Sang In Lee1, Man Hoon Han2, Yong-Jin Kim2, Min Hyun Cho1.
Abstract
BACKGROUND: There have been some cases where abnormal histopathologic findings could not be found in the kidney could even with proper specimen collection through percutaneous renal biopsy (PRB) in accordance with its indication. We analyzed the incidence and clinical outcomes of children who showed normal histopathological findings in their PRBs.Entities:
Keywords: Biopsy; Child; Hematuria; Proteinuria
Year: 2021 PMID: 34781639 PMCID: PMC8816418 DOI: 10.23876/j.krcp.21.091
Source DB: PubMed Journal: Kidney Res Clin Pract ISSN: 2211-9132
Figure 1.Flowchart of the study.
CHP, combined hematuria and proteinuria; eGFR, estimated glomerular filtration rate; IP, isolated proteinuria; PMH, isolated persistent microscopic hematuria; PRB, percutaneous renal biopsy.
Histopathological diagnoses in 526 patients
| Diagnose | RGH (n = 39) | PMH (n = 149) | CHP (n = 216) | IP (n = 100) | Others (n = 22) | Total (n = 526) |
|---|---|---|---|---|---|---|
| IgAN | 13 | 16 | 60 | 1 | 2 | 92 (17.5) |
| TBMN | 10 | 103 | 21 | 0 | 2 | 136 (25.9) |
| MCD | 1 | 0 | 2 | 53 | 0 | 56 (10.6) |
| MGN | 0 | 1 | 5 | 4 | 0 | 10 (1.9) |
| MPGN | 0 | 1 | 5 | 1 | 0 | 7 (1.3) |
| FSGS | 0 | 0 | 7 | 19 | 1 | 27 (5.1) |
| PSGN | 1 | 0 | 2 | 0 | 0 | 3 (0.6) |
| Alport disease | 1 | 1 | 13 | 0 | 0 | 15 (2.9) |
| HSP nephritis | 1 | 8 | 60 | 4 | 0 | 73 (13.9) |
| SLE nephritis | 0 | 2 | 13 | 4 | 6 | 25 (4.8) |
| HUS | 0 | 0 | 2 | 0 | 1 | 3 (0.6) |
| IgAN + TBMN | 3 | 5 | 7 | 1 | 0 | 16 (3.0) |
| MCD+TBMN | 0 | 0 | 4 | 5 | 0 | 9 (1.7) |
| HSP nephritis+TBMN | 0 | 1 | 5 | 0 | 0 | 6 (1.1) |
| TINU syndrome | 0 | 0 | 0 | 2 | 0 | 2 (0.4) |
| TIN | 0 | 0 | 0 | 0 | 4 | 4 (0.8) |
| ESRD | 0 | 0 | 0 | 1 | 2 | 3 (0.6) |
| Others | 0 | 1 | 4 | 1 | 1 | 7 (1.3) |
| No diagnostic abnormality | 9 | 10 | 6 | 4 | 3 | 32 (6.1) |
Data are expressed as number only or number (%).
CHP, combined hematuria and proteinuria; ESRD, end-stage kidney disease; FSGS, focal segmental glomerulosclerosis; HSP, Henoch-Schönlein purpura; HUS, hemolytic uremic syndrome; IgAN, immunoglobulin A nephropathy; IP, isolated proteinuria; MCD, minimal change disease; MGN, membranous glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; PMH, isolated persistent microscopic hematuria; PSGN, poststreptococcal glomerulonephritis; RGH, recurrent gross hematuria; SLE, systemic lupus erythematosus; TBMN, thin basement membrane nephropathy; TIN, tubulointerstitial nephritis; TINU, tubulointerstitial nephritis and uveitis.
Baseline characteristics of the patients with normal histopathological findings
| Characteristic | Data |
|---|---|
| Demographic | |
| Patients with normal PRB findings | 32 (6.1) |
| Sex, male/female | 21 (65.6)/11 (34.4) |
| Age at initial visit (yr) | 10.6 ± 4.1 |
| Age at renal biopsy (yr) | 11.4 ± 3.8 |
| Indication for PRB | |
| RGH | 9 (28.1) |
| PMH | 10 (31.3) |
| CHP | 6 (18.8) |
| IP | 4 (12.5) |
| Other renal insufficiencies | 3 (9.4) |
| Laboratory investigation | |
| Hemoglobin (g/dL) | 13.5 ± 1.5 |
| Platelet (×103/μL) | 283.4 ± 64.8 |
| Serum albumin (g/dL) | 4.6 ± 0.3 |
| Creatinine (mg/dL) | 0.6 ± 0.2 |
| eGFR (mL/min/1.73 m2) | 105.6 ± 36.2 |
| Histopathological finding | |
| No. of glomeruli | 15.7 ± 12.2 |
Data are expressed as number (%) or mean ± standard deviation.
CHP, combined hematuria and proteinuria; eGFR, estimated glomerular filtration rate; IP, isolated proteinuria; PMH, isolated persistent microscopic hematuria; PRB, percutaneous renal biopsy; RGH, recurrent gross hematuria.
Figure 2.Incidence rate of normal renal histopathology according to indications for biopsy
The dashed line represents the total incidence rate of normal renal histopathology in the 526 subjects (32 of 526, 6.1%).
RGH, recurrent gross hematuria; PMH, isolated persistent microscopic hematuria; IP, Isolated proteinuria; CHP, combined hematuria and proteinuria.
Results of follow-up observations according to major urine abnormalities
| Follow-up results by urine abnormality at the first visit | Follow-up patient |
|---|---|
| RGH | 8 |
| Gross hematuria | 1 (12.5) |
| Microscopic hematuria | 1 (12.5) |
| No hematuria | 6 (75.0) |
| PMH | 8 |
| Isolated microscopic hematuria | 4 (50.0) |
| No microscopic hematuria | 4 (50.0) |
| CHP | 5 |
| Hematuria and proteinuria | 0 (0) |
| Hematuria | 1 (20.0) |
| No abnormality in urine analysis | 4 (80.0) |
| IP | 4 |
| Proteinuria | 3 (75.0) |
| No abnormality in urine analysis | 1 (25.0) |
| Other renal insufficiencies | 3 |
| Persistent renal insufficiency | 1 (33.3) |
| Improved symptoms and no abnormality in urine analysis | 2 (66.7) |
Data are expressed as number only or number (%). Follow-up duration, 35.5 ± 23.6 months.
CHP, combined hematuria and proteinuria; IP, isolated proteinuria; PMH, isolated persistent microscopic hematuria; RGH, recurrent gross hematuria.